Rakowska Adriana, Gradzińska Agnieszka, Olszewska Małgorzata, Rudnicka Lidia
J Drugs Dermatol. 2017 Oct 1;16(10):988-992.
This study aimed to assess the efficacy of systemic retinoids in treating frontal fibrosing alopecia (FFA). It was based on a retrospective analysis of 54 female patients with FFA treated with: oral isotretinoin at the daily dose of 20 mg (29/54) or acitretin at the daily dose of 20 mg (11/54) or with oral finasteride 5 mg/daily (14/54). The study was conducted between 2007 and 2017. The basic of the study is the measurement of distance between the frontal hairline and the glabellar crease prior to the commencement of treatment and after 6, 12, and 24 months. The treatment with systemic retinoids lasted between 12 and 16 months (the mean duration of treatment was 13.5 months). The primary treatment goal was defined as no further progression of disease after 12 months of treatment, while the secondary treatment goal was defined as no further progression of disease following the discontinuation of systemic retinoids. The primary treatment goal was achieved by 76% (23/29) of patients treated with isotretinoin, 73% (8/11) of patients treated with acitretin, and 43% (6/14) of patients treated with finasteride. The secondary treatment goal was achieved by 72% (21/29) of patients treated with isotretinoin, 73% (8/11) of patients treated with acitretin, and 43% (6/14) of patients treated with finasteride. Thus, the administration of systemic retinoids may be beneficial for the stabilization of frontal hairline in patients with FFA.
J Drugs Dermatol. 2017;16(10):988-992.
.本研究旨在评估系统性维甲酸治疗额部纤维性脱发(FFA)的疗效。该研究基于对54例FFA女性患者的回顾性分析,这些患者接受了以下治疗:每日剂量20 mg的口服异维A酸(29/54)、每日剂量20 mg的阿维A(11/54)或每日5 mg的口服非那雄胺(14/54)。研究于2007年至2017年进行。研究的基础是在治疗开始前以及治疗6个月、12个月和24个月后测量额发际线与眉间皱纹之间的距离。系统性维甲酸治疗持续12至16个月(平均治疗持续时间为13.5个月)。主要治疗目标定义为治疗12个月后疾病无进一步进展,而次要治疗目标定义为停用系统性维甲酸后疾病无进一步进展。接受异维A酸治疗的患者中有76%(23/29)实现了主要治疗目标,接受阿维A治疗的患者中有73%(8/11)实现了主要治疗目标,接受非那雄胺治疗的患者中有43%(6/14)实现了主要治疗目标。接受异维A酸治疗的患者中有72%(21/29)实现了次要治疗目标,接受阿维A治疗的患者中有73%(8/11)实现了次要治疗目标,接受非那雄胺治疗的患者中有43%(6/14)实现了次要治疗目标。因此,系统性维甲酸的给药可能有利于稳定FFA患者的额发际线。
《药物皮肤病学杂志》。2017年;16(10):988 - 992。